Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [¹¹C]docetaxel and Positron Emission Tomography

Astrid A.M. van der Veldt, Mark Lubberink, Ron H.J. Mathijssen, Walter J. Loos, Gerarda J.M. Herder, Henri N. Greuter, Emile F.I. Comans, Hugo B. Rutten, Jonas Eriksson, Albert D. Windhorst, N. Harry Hendrikse, Pieter E. Postmus, Egbert F. Smit, Adriaan A. Lammertsma

Clin Cancer Res (2013) 19 (15): 4163–4173.

https://doi.org/10.1158/1078-0432.CCR-12-3779

Published: 31 July 2013

View article titled, Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography

Includes: Supplementary data

Journal Articles

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Karel Eechoute, Martin N. Fransson, An K. Reyners, Floris A. de Jong, Alex Sparreboom, Winette T.A. van der Graaf, Lena E. Friberg, Gaia Schiavon, Erik A.C. Wiemer, Jaap Verweij, Walter J. Loos, Ron H.J. Mathijssen, Ugo De Giorgi

Clin Cancer Res (2012) 18 (20): 5780–5787.

https://doi.org/10.1158/1078-0432.CCR-12-0490

Published: 14 October 2012

View article titled, A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Includes: Supplementary data

Journal Articles

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

Anne-Joy M. de Graan, Walter J. Loos, Lena E. Friberg, Sharyn D. Baker, Jessica M. van der Bol, Leni van Doorn, Erik A.C. Wiemer, Bronno van der Holt, Jaap Verweij, Ron H.J. Mathijssen

Clin Cancer Res (2012) 18 (16): 4425–4432.

https://doi.org/10.1158/1078-0432.CCR-12-0728

Published: 14 August 2012

View article titled, Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

Includes: Supplementary data

Journal Articles

Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

Anne-Joy M. de Graan, Cynthia S. Lancaster, Amanda Obaidat, Bruno Hagenbuch, Laure Elens, Lena E. Friberg, Peter de Bruijn, Shuiying Hu, Alice A. Gibson, Gitte H. Bruun, Thomas J. Corydon, Torben S. Mikkelsen, Aisha L. Walker, Guoqing Du, Walter J. Loos, Ron H. N. van Schaik, Sharyn D. Baker, Ron H. J. Mathijssen, Alex Sparreboom

Clin Cancer Res (2012) 18 (16): 4433–4440.

https://doi.org/10.1158/1078-0432.CCR-12-0761

Published: 14 August 2012

View article titled, Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

Includes: Supplementary data

Journal Articles

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M. Franke, Gaia Schiavon, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer, Ron H.J. Mathijssen

Clin Cancer Res (2011) 17 (3): 406–415.

https://doi.org/10.1158/1078-0432.CCR-10-2250

Published: 01 February 2011

View article titled, Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

Journal Articles

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

Frederike K. Engels, Walter J. Loos, Jessica M. van der Bol, Peter de Bruijn, Ron H.J. Mathijssen, Jaap Verweij, Ron A.A. Mathot

Clin Cancer Res (2011) 17 (2): 353–362.

https://doi.org/10.1158/1078-0432.CCR-10-1636

Published: 16 January 2011

View article titled, Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

Journal Articles

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

Cynthia S. Lancaster, Chaoxin Hu, Ryan M. Franke, Kelly K. Filipski, Shelley J. Orwick, Zhaoyuan Chen, Zhili Zuo, Walter J. Loos, Alex Sparreboom

Clin Cancer Res (2010) 16 (19): 4789–4799.

https://doi.org/10.1158/1078-0432.CCR-10-1239

Published: 29 September 2010

View article titled, Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

Journal Articles

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

Jessica M. van der Bol, Ron H.J. Mathijssen, Geert-Jan M. Creemers, André S.Th. Planting, Walter J. Loos, Erik A.C. Wiemer, Lena E. Friberg, Jaap Verweij, Alex Sparreboom, Floris A. de Jong

Clin Cancer Res (2010) 16 (2): 736–742.

https://doi.org/10.1158/1078-0432.CCR-09-1526

Published: 14 January 2010

View article titled, A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

Includes: Supplementary data

Journal Articles

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Constantijne H. Mom, Jaap Verweij, Corina N.A.M. Oldenhuis, Jourik A. Gietema, Norma Lynn Fox, Renée Miceli, Ferry A.L.M. Eskens, Walter J. Loos, Elisabeth G.E. de Vries, Stefan Sleijfer

Clin Cancer Res (2009) 15 (17): 5584–5590.

https://doi.org/10.1158/1078-0432.CCR-09-0996

Published: 31 August 2009

View article titled, Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Includes: Supplementary data

Journal Articles

Interaction of Cisplatin with the Human Organic Cation Transporter 2

Kelly K. Filipski, Walter J. Loos, Jaap Verweij, Alex Sparreboom

Clin Cancer Res (2008) 14 (12): 3875–3880.

https://doi.org/10.1158/1078-0432.CCR-07-4793

Published: 16 June 2008

View article titled, Interaction of Cisplatin with the Human Organic Cation Transporter 2

Journal Articles

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

Anja Henningsson, Sharon Marsh, Walter J. Loos, Mats O. Karlsson, Adam Garsa, Klaus Mross, Stephan Mielke, Lucia Viganò, Alberta Locatelli, Jaap Verweij, Alex Sparreboom, Howard L. McLeod

Clin Cancer Res (2005) 11 (22): 8097–8104.

https://doi.org/10.1158/1078-0432.CCR-05-1152

Published: 18 November 2005

View article titled, Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

Journal Articles

Structural Identification and Biological Activity of 7-Methyl-10,11-Ethylenedioxy-20( S )-Camptothecin, a Photodegradant of Lurtotecan

Walter J. Loos, Jaap Verweij, Diederik F. S. Kehrer, Peter de Bruijn, Franciscus M. H. de Groot, Marta Hamilton, Kees Nooter, Gerrit Stoter, Alex Sparreboom

Clin Cancer Res (2002) 8 (3): 856–862.

Published: 01 March 2002

View article titled, Structural Identification and Biological Activity of 7-Methyl-10,11-Ethylenedioxy-20( S )-Camptothecin, a Photodegradant of Lurtotecan

Journal Articles

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Ron H. J. Mathijssen, Robbert J. van Alphen, Jaap Verweij, Walter J. Loos, Kees Nooter, Gerrit Stoter, Alex Sparreboom

Clin Cancer Res (2001) 7 (8): 2182–2194.

Published: 01 August 2001

View article titled, Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Journal Articles

Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens

Walter J. Loos, Hans Gelderblom, Alex Sparreboom, Jaap Verweij, Maja J. A. de Jonge

Clin Cancer Res (2000) 6 (7): 2685–2689.

Published: 01 July 2000

View article titled, Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens

Journal Articles

Topotecan Lacks Third Space Sequestration

Hans Gelderblom, Walter J. Loos, Jaap Verweij, Maja J. A. de Jonge, Alex Sparreboom

Clin Cancer Res (2000) 6 (4): 1288–1292.

Published: 01 April 2000

View article titled, Topotecan Lacks Third Space Sequestration

Journal Articles

A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin)

Cees J. H. Gerrits, Jan H. M. Schellens, Howard Burris, John R. Eckardt, Andre S. T. Planting, Maria E. L. van der Burg, Gail I. Rodriguez, Walter J. Loos, Vera van Beurden, Ian Hudson, Daniel D. Von Hoff, Jaap Verweij

Clin Cancer Res (1999) 5 (1): 69–75.

Published: 01 January 1999

View article titled, A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin)

NARROW

Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [¹¹C]docetaxel and Positron Emission Tomography

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Interaction of Cisplatin with the Human Organic Cation Transporter 2

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

Structural Identification and Biological Activity of 7-Methyl-10,11-Ethylenedioxy-20( S )-Camptothecin, a Photodegradant of Lurtotecan

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens

Topotecan Lacks Third Space Sequestration

A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin)

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only